Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Amiloride HCl
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Stress and the risk of multiple sclerosis.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Laquinimod

Pages